PMID- 23791610
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20161125
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 714
IP  - 1-3
DP  - 2013 Aug 15
TI  - Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats 
      fed with high fructose diet through inhibition of sterol regulatory element 
      binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator 
      activated receptor alpha (Pparalpha).
PG  - 89-95
LID - S0014-2999(13)00479-2 [pii]
LID - 10.1016/j.ejphar.2013.06.013 [doi]
AB  - The aim of this study was to examine the therapeutic effect of oxymatrine, a 
      monomer isolated from the medicinal plant Sophora flavescens Ait, on the hepatic 
      lipid metabolism in non-alcoholic fatty liver (NAFLD) rats and to explore the 
      potential mechanism. Rats were fed with high fructose diet for 8 weeks to 
      establish the NAFLD model, then were given oxymatrine treatment (40, 80, and 160 
      mg/kg, respectively) for another 8 weeks. Body weight gain, liver index, serum 
      and liver lipids, and histopathological evaluation were measured. Enzymatic 
      activity and gene expression of the key enzymes involved in the lipogenesis and 
      fatty acid oxidation were assayed. The results showed that oxymatrine treatment 
      reduced body weight gain, liver weight, liver index, dyslipidemia, and liver 
      triglyceride level in a dose dependant manner. Importantly, the histopathological 
      examination of liver confirmed that oxymatrine could decrease the liver lipid 
      accumulation. The treatment also decreased the fatty acid synthase (FAS) 
      enzymatic activity and increased the carnitine palmitoyltransferase 1A (CPT1A) 
      enzymatic activity. Besides, oxymatrine treatment decreased the mRNA expression 
      of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid 
      synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA 
      expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine 
      palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose 
      diet induced NAFLD rats. These results suggested that the therapeutic effect of 
      oxymatrine on the hepatic steatosis in high fructose diet induced fatty liver 
      rats is partly due to down-regulating Srebf1 and up-regulating Pparalpha mediated 
      metabolic pathways simultaneously.
CI  - (c) 2013 Elsevier B.V. All rights reserved.
FAU - Shi, Li-juan
AU  - Shi LJ
AD  - Department of Endocrinology, The Third Hospital of Shijiazhuang City Affiliated 
      to Hebei Medical University, Shijiazhuang 050011, China.
FAU - Shi, Lei
AU  - Shi L
FAU - Song, Guang-yao
AU  - Song GY
FAU - Zhang, He-fang
AU  - Zhang HF
FAU - Hu, Zhi-juan
AU  - Hu ZJ
FAU - Wang, Chao
AU  - Wang C
FAU - Zhang, Dong-hui
AU  - Zhang DH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130618
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Alkaloids)
RN  - 0 (Fatty Acids)
RN  - 0 (PPAR alpha)
RN  - 0 (Quinolizines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Srebf1 protein, rat)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
RN  - 30237-26-4 (Fructose)
RN  - 85U4C366QS (oxymatrine)
SB  - IM
MH  - Alkaloids/*pharmacology/therapeutic use
MH  - Animals
MH  - Body Weight/drug effects
MH  - Diet/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Dyslipidemias/complications/drug therapy
MH  - Energy Intake/drug effects
MH  - Fatty Acids/metabolism
MH  - Fatty Liver/*drug therapy/genetics/metabolism/pathology
MH  - Fructose/*adverse effects
MH  - Gene Expression Regulation/drug effects
MH  - Liver/drug effects/metabolism/pathology
MH  - Male
MH  - Non-alcoholic Fatty Liver Disease
MH  - Oxidation-Reduction/drug effects
MH  - PPAR alpha/genetics/*metabolism
MH  - Quinolizines/*pharmacology/therapeutic use
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Signal Transduction/drug effects
MH  - Sterol Regulatory Element Binding Protein 1/*antagonists & 
      inhibitors/genetics/metabolism
OTO - NOTNLM
OT  - Fatty acid oxidation
OT  - Fatty acid synthesis
OT  - Liver steatosis
OT  - Oxymatrine
EDAT- 2013/06/25 06:00
MHDA- 2014/05/07 06:00
CRDT- 2013/06/25 06:00
PHST- 2013/02/18 00:00 [received]
PHST- 2013/06/01 00:00 [revised]
PHST- 2013/06/08 00:00 [accepted]
PHST- 2013/06/25 06:00 [entrez]
PHST- 2013/06/25 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
AID - S0014-2999(13)00479-2 [pii]
AID - 10.1016/j.ejphar.2013.06.013 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2013 Aug 15;714(1-3):89-95. doi: 10.1016/j.ejphar.2013.06.013. 
      Epub 2013 Jun 18.